Oryzon obtains orphan designation for ORY-1001 for the treatment of Acute Myeloid Leukemia from the European Medicines Agency
Oryzon announced today that it has received from EMA the orphan designation for ORY-1001, an inhibitor of LSD1 for the treatment of Acute Myeloid Leukemia.
Oryzon has received from the Committee for Orphan Medicinal Products (COMP), the committee at the European Medicines Agency that is responsible for reviewing applications for 'orphan-medicinal-product designation', the positive opinion on its application for orphan designation of ORY-1001 for the treatment of Acute Myeloid Leukemia (AML) after the meeting held by the COMP in London on July 9-11.
